Apply to Become Molecular Therapy's Next Editor-in-Chief

The Editor-in-Chief (EIC) is responsible for carrying out the mission of ASGCT's Molecular Therapy, which is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials.

Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2022 impact factor is 12.4. Apply to serve a five-year term beginning Jan. 1, 2025.

Learn more & apply

The EIC Will:

• Undertake responsibility, authority, and accountability for all peer-reviewed content and invited front matter published in the journal and on the journal website.
• Oversee the strategic direction of the journal. Assume overall responsibility for maintaining the journal’s scientific scope and determining its editorial direction.
• Serve as an ambassador and an advocate for the journal and ASGCT, and represent the journal at scientific and educational events, continuously building relationships within the gene and cell therapy community. Read the rest of the responsibilities and requirements here.

Apply for MT EIC Position

Related Articles